The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in lung cancer:

PROTOCOL: GS-US-577-6153 (EVOKE-01) (PI: DR KEN O’BYRNE)

Protocol Title: Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations and with Progression on or After Platinum Based Chemotherapy and anti PD 1/PD L1 Immunotherapy

Lay Title: Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy

Click here for more information

PROTOCOL: BGB-A317-Sitravatinib 301 (PI: DR KEN O’BYRNE)

Protocol Title: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody

Lay Title: Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Click here for more information

PROTOCOL: CA001-050 (PI: DR KEN O’BYRNE)

Protocol Title: A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Lay Title: A Study of BMS-986012 in Combination With Carboplatin, Etoposide,  and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Click here for more information